08:51 AM EDT, 11/01/2024 (MT Newswires) -- Lexicon Pharmaceuticals ( LXRX ) said late Thursday that the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration voted 11-3 against recommending Zynquista (sotagliflozin) as an add-on to insulin therapy for glycemic control in adults suffering from type 1 diabetes and chronic kidney disease. The committee cited concerns that the benefits do not outweigh the risks.

Although the vote is non-binding, the FDA will consider it in its final decision, expected on Dec. 20, Lexicon said.

Lexicon shares plunged nearly 39% in recent premarket activity.

Price: 1.2000, Change: -0.75, Percent Change: -38.46